贝伐珠单抗联合卡铂和紫杉醇对比卡铂和紫杉醇单药治疗初治局部晚期或转移性非小细胞肺癌的随机II期试验
这项随机II期试验将99例初治局部晚期或转移性非小细胞肺癌患者随机分为三组:贝伐珠单抗7.5 mg/kg联合卡铂和紫杉醇组(n=32)、贝伐珠单抗15 mg/kg联合卡铂和紫杉醇组(n=35)以及卡铂和紫杉醇单药组(n=32)。与对照组相比,贝伐珠单抗15 mg/kg联合化疗组提高了缓解率(31.5% vs 18.8%),延长了中位疾病进展时间(7.4 vs 4.2个月),并适度延长了生存期(17.7 vs 14.9个月)。咯血是最突出的不良事件,大咯血与鳞状细胞组织学、肿瘤坏死和空洞形成以及病变靠近大血管相关。
要点
- 贝伐珠单抗15 mg/kg联合卡铂和紫杉醇较单纯化疗提高缓解率(31.5% vs 18.8%),延长中位疾病进展时间(7.4 vs 4.2个月),并适度延长生存期(17.7 vs 14.9个月)。
- 出血是最突出的不良事件,表现为两种临床模式:轻微黏膜皮肤出血和大咯血。
- 大咯血与鳞状细胞组织学、肿瘤坏死和空洞形成以及病变靠近大血管相关;非鳞状细胞组织学患者似乎预后改善且安全风险可接受。
核心结论
- 贝伐珠单抗联合卡铂和紫杉醇改善了晚期或复发性非小细胞肺癌患者的总体缓解率和疾病进展时间。
- 非鳞状细胞组织学患者似乎是预后改善且安全风险可接受的亚群。
研究设计与样本
- 随机II期试验,99例初治局部晚期或转移性非小细胞肺癌患者随机分配至贝伐珠单抗7.5 mg/kg联合卡铂(曲线下面积=6)和紫杉醇(200 mg/m2)每3周组(n=32)、贝伐珠单抗15 mg/kg联合卡铂和紫杉醇每3周组(n=35)或卡铂和紫杉醇单药组(n=32)。
- 主要疗效终点为疾病进展时间和最佳确认缓解率。
- 疾病进展后,对照组患者可选择接受单药贝伐珠单抗15 mg/kg每3周治疗。
主要发现
- 与对照组相比,卡铂和紫杉醇联合贝伐珠单抗15 mg/kg组缓解率更高(31.5% vs 18.8%),中位疾病进展时间更长(7.4 vs 4.2个月),生存期适度增加(17.7 vs 14.9个月)。
- 19例对照组患者交叉接受单药贝伐珠单抗治疗,其中5例疾病稳定,1年生存率为47%。
- 出血是最突出的不良事件,表现为两种不同的临床模式:轻微黏膜皮肤出血和大咯血。
- 大咯血与鳞状细胞组织学、肿瘤坏死和空洞形成以及病变靠近大血管相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. PATIENTS AND METHODS: In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m2) every 3 weeks or carboplatin and paclitaxel alone (n = 32). Primary efficacy end points were time to disease progression and best confirmed response rate. On disease progression, patients in the control arm had the option to receive single-agent bevacizumab 15 mg/kg every 3 weeks. RESULTS: Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 months) and a modest increase in survival (17.7 v 14.9 months). Of the 19 control patients that crossed over to single-agent bevacizumab, five experienced stable disease, and 1-year survival was 47%. Bleeding was the most prominent adverse event and was manifested in two distinct clinical patterns; minor mucocutaneous hemorrhage and major hemoptysis. Major hemoptysis was associated with squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels. CONCLUSION: Bevacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer. Patients with nonsquamous cell histology appear to be a subpopulation with improved outcome and acceptable safety risks.
引用
- Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 37126944. doi:10.1200/JCO.22.02543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。